New drug combo shows promise for hard-to-treat skin cancer
NCT ID NCT04640545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called LBL-007 combined with two other medicines (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers also looked at whether the treatment shrank tumors. This is not a cure, but aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410006, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic drug shrink advanced melanoma tumors?
- Engineered immune cells take aim at Hard-to-Treat cancers
- Could a diabetes drug boost immunotherapy in advanced melanoma?
- New combo therapy takes on advanced cancers
- Wheat germ supplement studied for immune boost in advanced cancer
- Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?